Efficacy and Safety of Vardenafil in Renal Transplant Recipients With Erectile Dysfunction

Demir, Erkan; Balal, Mustafa; Paydaş, Saime; Sertdemır, Yaşar; Erken, U.

doi:10.1016/j.transproceed.2006.02.076

Cited by 31 publications

(23 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2,12 Heterogeneity was not observed in the analysis (I 2 , 0%). The mean creatinine clearance for vardenafil (70 mg/min) and placebo (74 mg/min) showed mean difference of the change -4.44 mg/min (95% CI: -10.34 to 1.46), and there was no significant difference between PDE-5 inhibitors and placebo ( Figure 4B).…”

Section: Literature Reviewmentioning

confidence: 86%

Section: Literature Reviewmentioning

confidence: 99%

“…2,11,12 The 3 studies included studies of vardenafil (2 studies) or sildenafil (1 study) against placebo (Table 1). 2,11,12 efficacy All 3 studies reported the change in the IIEF score from baseline to endpoint. 2,11,12 In 2 studies (total, 99 patients) that evaluated vardenafil against placebo, ED was assessed using IIEF questions 1 to 5 and 15.…”

Section: Literature Reviewmentioning

confidence: 99%

“…2,11,12 efficacy All 3 studies reported the change in the IIEF score from baseline to endpoint. 2,11,12 In 2 studies (total, 99 patients) that evaluated vardenafil against placebo, ED was assessed using IIEF questions 1 to 5 and 15. 2,12 In the study (64 patients) that evaluated sildenafil against placebo, ED was assessed using the 5 domains of the IIEF survey.…”

Section: Literature Reviewmentioning

confidence: 99%

“…2,11,12 In 2 studies (total, 99 patients) that evaluated vardenafil against placebo, ED was assessed using IIEF questions 1 to 5 and 15. 2,12 In the study (64 patients) that evaluated sildenafil against placebo, ED was assessed using the 5 domains of the IIEF survey. Therefore, we used subgroup analysis to eliminate heterogeneity.…”

Section: Literature Reviewmentioning

confidence: 99%

See 4 more Smart Citations

Untitled

2014

Exp Clin Transplant

View full text Add to dashboard Cite

Objectives: Erectile dysfunction is common after kidney transplant. The phosphodiesterase-5 inhibitors are the primary drugs for the treatment of erectile dysfunction. The purpose of this study was to evaluate the efficacy and safety of these drugs in the treatment of erectile dysfunction after kidney transplant. Materials and Methods: Randomized controlled trials were identified and extracted from MEDLINE, the Web of Science, Cochrane Central, and reference lists. The database search, quality assessment, and data extraction were performed independently by 2 reviewers. Eligible studies were randomized controlled trials and quasi-randomized controlled trials. Treatment efficacy was assessed with the International Index of Erectile Function score. Results: There were 3 studies identified that satisfied inclusion criteria. The International Index of Erectile Function score for phosphodiesterase-5 inhibitors increased ≥ 9 points compared with placebo (mean difference, 11.81; 95% confidence interval: 9.14-14.48; P < .00001). There were no differences between the phosphodiesterase-5 inhibitors and placebo in the incidence of adverse events, creatinine levels, or concentrations of cyclosporine or tacrolimus. Conclusions: Phosphodiesterase-5 inhibitors are effective and safe in treating erectile dysfunction after kidney transplant. Phosphodiesterase-5 inhibitors do not cause changes in kidney function or immunosuppressive drug concentrations after kidney transplant and may be used as the first-line treatment for erectile dysfunction in kidney transplant recipients.

show abstract

Section: Literature Reviewmentioning

confidence: 86%